Clinical Trial Detail

NCT ID NCT02926768
Title Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Checkpoint Therapeutics, Inc.
Indications

Advanced Solid Tumor

lung non-small cell carcinoma

Therapies

CK-101

Age Groups: adult senior

No variant requirements are available.